Insulin degludec

Drug Profile

Insulin degludec

Alternative Names: Insulin decludec; NN-1250; SIBA; Soluble insulin basal analogue; Tresiba

Latest Information Update: 26 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Novo Nordisk
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • No development reported Diabetes mellitus

Most Recent Events

  • 14 Jun 2017 Novo Nordisk files type II variation application to the EMA to include data from the phase III DEVOTE trial for Type 2 diabetes mellitus
  • 12 Jun 2017 Efficacy and adverse events data from the phase III DEVOTE trial in Type-2 diabetes mellitus released by Novo Nordisk
  • 27 May 2017 Novo Nordisk files sNDA for label expansion for treatment of patients with Type 2 diabetes mellitus in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top